Genome Editing Drugs Landscape: Comprehensive Analysis of Current Drugs and Dynamics

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Genome Editing Drugs Landscape report delivers a comprehensive analysis of the current and emerging genome editing therapies shaping the pharmaceutical industry. Viewed through the lens of drug development, clinical progress, regulatory evolution, and commercial performance, the report helps stakeholders understand how genome editing technologies are transitioning from experimental platforms to viable therapeutic solutions.

By combining clinical pipeline analysis, regulatory developments, and market performance insights, the report highlights the key forces reshaping the genome editing landscape. It enables readers to identify high-potential technologies, leading companies, and future growth opportunities, while providing a clear view of where the market is heading and how strategies must adapt to remain competitive.

Scope

This 48-page in-depth report, supported by 19 data-rich figures, delivers expert insight into the global genome editing drug landscape, including:

  • Analysis of established and next-generation genome editing technologies, including current and emerging modalities

  • Evaluation of clinical pipelines, development stages, and therapeutic focus areas

  • Assessment of regulatory progress and hurdles influencing development timelines and commercialization

  • Review of market performance, sales, and forecasts for leading genome editing drugs

  • Identification of key players shaping the competitive landscape and the strategies driving their success

How industry leaders are using this report

Leading companies and investors use this report to:

  • Guide portfolio and pipeline prioritization by identifying the most promising genome editing technologies and indications

  • Support investment and valuation decisions with clear visibility into sales performance, forecasts, and competitive positioning

  • Accelerate partnership and acquisition strategies by pinpointing emerging leaders and under-the-radar innovators

  • Anticipate regulatory and clinical inflection points that could reshape the genome editing market

  • Reduce strategic risk by aligning R&D, BD, and capital deployment decisions with validated market and pipeline data

Reasons to Buy

This report enables you to:

  • Understand the full spectrum of genome editing technologies, including established approaches and novel next-generation platforms

  • Track historical shifts and inflection points that have shaped today’s genome editing market

  • Identify leading genome editing drugs based on current sales, forecast performance, and competitive positioning

  • Assess therapeutic areas and indications where genome editing is gaining the strongest traction

  • Spot future opportunities and emerging leaders as genome editing moves toward broader clinical and commercial adoption

Who should buy this report

  • Pharmaceutical and Biotechnology Companies
  • Large Pharmaceutical Companies and Business Development Teams
  • Small and Mid-sized Biotechnology Firms
  • Investors, Venture Capital, and Private Equity Firms
  • Life Sciences Strategy and Portfolio Planning Teams
  • Consultants and Strategic Advisors

CRISPR Therapeutics
Intellia Therapeutics
YolTech Therapeutics
Cellectis
Sangamo Therapeutics
Modalis Therapeutics
Metagenomi
Prime Medicine
Vertex Pharmaceuticals
Huldagene Therapeutics
Beam Therapeutics
Shanghai BDgene Therapeutics
General Hospital of the People's Liberation Army
Regeneron Pharmaceuticals
KSQ Therapeutics
CorrectSequence Therapeutics Co Ltd
Caribou Biosciences Inc
Genentech Inc
Allogene therapeutics Inc
Renji Hospital
Vor Biopharma
MeiraFTx Holdings Plc
City of Hope

Table of Contents

Table of Contents

1 Introduction to Genome Editing

1.1 Description of the different genome editing subtypes

1.2 Spotlight: Casgevy

2 Genome Editors: Previous Years in Review

2.1 Patent trends

2.2 Review designation trends

2.3 Deals value and volume review

3 Genome Editors: Current Landscape

3.1 Genome editor trends by subtype, development stage, indications

3.2 Most active companies in genome editing development

3.3 Top deals by type

3.4 Top clinical trial sponsors

4 Genome Editors: Current Landscape

4.1 Top companies by genome editing forecast sales

4.2 Top genome editors by forecast sales

4.3 Total genome editing market forecast sales

4.4 Upcoming genome editing launches

4.5 Genome editors by highest likelihood of approval (LoA)

5 Key Findings

6 Appendix

6.1 Abbreviations

6.2 Methodology

6.3 About the Authors

6.4 About GlobalData

6.5 Contact Us

Genome Editing Drugs Landscape: Comprehensive Analysis of Current Drugs and Dynamics thematic reports
Currency USD
$1,200

Can be used by individual purchaser only

$2,700

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Genome Editing Drugs Landscape: Comprehensive Analysis of Current Drugs and Dynamics was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Genome Editing Drugs Landscape: Comprehensive Analysis of Current Drugs and Dynamics in real time.

  • Access a live Genome Editing Drugs Landscape: Comprehensive Analysis of Current Drugs and Dynamics dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.